search
Back to results

Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs

Primary Purpose

Diabetes, Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
insulin detemir
insulin aspart
biphasic insulin aspart 30
metformin
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  • Diagnosed type 2 diabetes (WHO 1999 criteria)
  • Currently treated with suboptimal daily dose of OADs (mono or combination therapy) for at least 6 months
  • Male or female age at least 18 years old
  • HbA1c at least 7.0 % and maximum 11.0% for subjects treated with metformin mono-therapy, or maximum 10% for subjects treated with OAD combination therapy
  • BMI maximum 40 kg/m^2
  • Able and willing to perform self-monitoring of plasma glucose according to the protocol and to keep a diary
  • Able and willing to be treated with up to 4 insulin injections per day

Exclusion Criteria:

  • Known or suspected allergy to trial product(s) or related products
  • Previous participation in this trial. Participation is defined as randomisation
  • Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)
  • Participated in another clinical trial and received an investigational drug within the last weeks prior to the present trial
  • Impaired hepatic function defined as alanine aminotransferase (ALT) or alkaline phosphatase (ALP) at least 2.5 times upper referenced limit
  • Impaired renal function defined as serum-creatinine at least 1.3 mg/dL (at least 115 mmol/L) for males and at least 1.2 mg/dL (at least 106 mmol/L) for females
  • Subject has a clinically significant, active (or over the past 12 months) cardiovascular history (including a history of myocardial infarction (MI), arrhythmias or conduction delays on ECG, unstable angina, or decompensated heart failure (New York Heart Association class III and IV)
  • Severe uncontrolled treated or untreated hypertension (sitting systolic blood pressure at least 180 mmHg or sitting diastolic blood pressure at least 100 mmHg)
  • Proliferative retinopathy or macular oedema requiring acute treatment
  • Metformin contraindications according to the package insert
  • Current treatment with systemic corticosteroids
  • Subject has a history of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering study drug to the subject
  • Current addiction to alcohol or other addictive substances as determined by the Investigator
  • Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation in the study or use of the glucose monitor
  • History of hypoglycaemic unawareness and/or two or more severe hypoglycaemic episodes in the past year as judged by the Investigator

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Detemir + Met

BIAsp 30 + Met

Arm Description

Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.

Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.

Outcomes

Primary Outcome Measures

Glycosylated Haemoglobin (HbA1c)
Estimated mean difference in HbA1c after 50 weeks of treatment

Secondary Outcome Measures

Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment
Observed mean change from baseline in HbA1c at Week 14 (visit 11)
Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
Observed mean change in from baseline in HbA1c at Week 26 (visit 18)
Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment
Observed mean change from baseline in HbA1c at Week 38 (visit 25)
Change in Glycosylated Haemoglobin (HbA1c) at Week 50
Observed mean change from baseline in HbA1c at Week 50 (visit 32)
Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment
Number of subjects achieving HbA1c below 7.0% after 14 weeks of treatment (visit 11)
Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment
Number of subjects achieving HbA1c below 7.0% after 26 weeks of treatment (visit 18)
Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment
Number of subjects achieving HbA1c below 7.0% after 38 weeks of treatment (visit 25)
Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment
Number of subjects achieving HbA1c below 7.0% after 50 weeks of treatment (visit 32)
Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment
Observed overall mean of PG increment after 14 weeks of treatment (Visit 11). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}
Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment
Observed overall mean of PG increment after 26 weeks of treatment (visit 18). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}
Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment
Observed overall mean of PG increment after 38 weeks of treatment (visit 25). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.
Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment
Observed overall mean of PG increment after 50 weeks of treatment (visit 32). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.
Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment
Observed overall mean of 8-point PG profile after 14 weeks of treatment (visit 11)
Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment
Observed overall mean of 8-point PG profile after 26 weeks of treatment (visit 18)
Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment
Observed overall mean of 8-point PG profile after 38 weeks of treatment (visit 25)
Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment
Observed overall mean of 8-point PG profile after 50 weeks of treatment (visit 32)

Full Information

First Posted
February 12, 2010
Last Updated
November 23, 2016
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT01068652
Brief Title
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
Official Title
Effect of 50-week Treatment With Stepwise Insulin Intensification of Basal-bolus Insulin Analogues (Insulin Detemir and Aspart) or Biphasic Insulin Aspart 30 (NovoMix 30) All in Combination With Fixed Dose of Metformin on Glycaemic Control (Measured as HbA1c) in Subjects With Type 2 Diabetes. Open Labelled, Randomized, Two-arm, Parallel Group, Multi-centre, Multi-national Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
May 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial is conducted in Africa. The aim of this clinical trial is to investigate the effect of 50 weeks of treatment with different intensified insulin administrations (all in combination with a fixed dose of metformin) on blood sugar control in subjects with type 2 diabetes inadequately controlled by oral anti-diabetic drugs (OADs).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
403 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Detemir + Met
Arm Type
Active Comparator
Arm Description
Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.
Arm Title
BIAsp 30 + Met
Arm Type
Active Comparator
Arm Description
Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
Intervention Type
Drug
Intervention Name(s)
insulin detemir
Intervention Description
Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
Intervention Type
Drug
Intervention Name(s)
insulin aspart
Intervention Description
Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
Intervention Type
Drug
Intervention Name(s)
biphasic insulin aspart 30
Intervention Description
Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
Intervention Type
Drug
Intervention Name(s)
metformin
Intervention Description
1000-2000 mg/day in combination with insulin treatment
Primary Outcome Measure Information:
Title
Glycosylated Haemoglobin (HbA1c)
Description
Estimated mean difference in HbA1c after 50 weeks of treatment
Time Frame
Week 50
Secondary Outcome Measure Information:
Title
Change in Glycosylated Haemoglobin (HbA1c) After 14 Weeks of Treatment
Description
Observed mean change from baseline in HbA1c at Week 14 (visit 11)
Time Frame
Week 0, Week 14
Title
Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
Description
Observed mean change in from baseline in HbA1c at Week 26 (visit 18)
Time Frame
Week 0, Week 26
Title
Change in Glycosylated Haemoglobin (HbA1c) After 38 Weeks of Treatment
Description
Observed mean change from baseline in HbA1c at Week 38 (visit 25)
Time Frame
Week 0, Week 38
Title
Change in Glycosylated Haemoglobin (HbA1c) at Week 50
Description
Observed mean change from baseline in HbA1c at Week 50 (visit 32)
Time Frame
Week 0, Week 50
Title
Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 14 Weeks of Treatment
Description
Number of subjects achieving HbA1c below 7.0% after 14 weeks of treatment (visit 11)
Time Frame
Week 14
Title
Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 26 Weeks of Treatment
Description
Number of subjects achieving HbA1c below 7.0% after 26 weeks of treatment (visit 18)
Time Frame
Week 26
Title
Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 38 Weeks of Treatment
Description
Number of subjects achieving HbA1c below 7.0% after 38 weeks of treatment (visit 25)
Time Frame
Week 38
Title
Number of Subjects Achieving Glycosylated Haemoglobin (HbA1c) Below 7.0% After 50 Weeks of Treatment
Description
Number of subjects achieving HbA1c below 7.0% after 50 weeks of treatment (visit 32)
Time Frame
Week 50
Title
Mean of Prandial Plasma Glucose (PG) Increment After 14 Weeks of Treatment
Description
Observed overall mean of PG increment after 14 weeks of treatment (Visit 11). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}
Time Frame
Week 14
Title
Mean of Prandial Plasma Glucose (PG) Increment After 26 Weeks of Treatment
Description
Observed overall mean of PG increment after 26 weeks of treatment (visit 18). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}
Time Frame
Week 26
Title
Mean of Prandial Plasma Glucose (PG) Increment After 38 Weeks of Treatment
Description
Observed overall mean of PG increment after 38 weeks of treatment (visit 25). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.
Time Frame
Week 38
Title
Mean of Prandial Plasma Glucose (PG) Increment After 50 Weeks of Treatment
Description
Observed overall mean of PG increment after 50 weeks of treatment (visit 32). Mean PG Increment was calculated using the average of difference between the Post Prandial and Pre Prandial Glucose values {ie .average of (Post Breakfast - Pre Breakfast), (Post Lunch - Pre Lunch) and (Post Dinner - Pre Dinner)}.
Time Frame
Week 50
Title
Mean of 8-point Plasma Glucose (PG) Profile After 14 Weeks of Treatment
Description
Observed overall mean of 8-point PG profile after 14 weeks of treatment (visit 11)
Time Frame
Week 14
Title
Mean of 8-point Plasma Glucose (PG) Profile After 26 Weeks of Treatment
Description
Observed overall mean of 8-point PG profile after 26 weeks of treatment (visit 18)
Time Frame
Week 26
Title
Mean of 8-point Plasma Glucose (PG) Profile After 38 Weeks of Treatment
Description
Observed overall mean of 8-point PG profile after 38 weeks of treatment (visit 25)
Time Frame
Week 38
Title
Mean of 8-point Plasma Glucose (PG) Profile After 50 Weeks of Treatment
Description
Observed overall mean of 8-point PG profile after 50 weeks of treatment (visit 32)
Time Frame
Week 50

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject) Diagnosed type 2 diabetes (WHO 1999 criteria) Currently treated with suboptimal daily dose of OADs (mono or combination therapy) for at least 6 months Male or female age at least 18 years old HbA1c at least 7.0 % and maximum 11.0% for subjects treated with metformin mono-therapy, or maximum 10% for subjects treated with OAD combination therapy BMI maximum 40 kg/m^2 Able and willing to perform self-monitoring of plasma glucose according to the protocol and to keep a diary Able and willing to be treated with up to 4 insulin injections per day Exclusion Criteria: Known or suspected allergy to trial product(s) or related products Previous participation in this trial. Participation is defined as randomisation Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) Participated in another clinical trial and received an investigational drug within the last weeks prior to the present trial Impaired hepatic function defined as alanine aminotransferase (ALT) or alkaline phosphatase (ALP) at least 2.5 times upper referenced limit Impaired renal function defined as serum-creatinine at least 1.3 mg/dL (at least 115 mmol/L) for males and at least 1.2 mg/dL (at least 106 mmol/L) for females Subject has a clinically significant, active (or over the past 12 months) cardiovascular history (including a history of myocardial infarction (MI), arrhythmias or conduction delays on ECG, unstable angina, or decompensated heart failure (New York Heart Association class III and IV) Severe uncontrolled treated or untreated hypertension (sitting systolic blood pressure at least 180 mmHg or sitting diastolic blood pressure at least 100 mmHg) Proliferative retinopathy or macular oedema requiring acute treatment Metformin contraindications according to the package insert Current treatment with systemic corticosteroids Subject has a history of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering study drug to the subject Current addiction to alcohol or other addictive substances as determined by the Investigator Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation in the study or use of the glucose monitor History of hypoglycaemic unawareness and/or two or more severe hypoglycaemic episodes in the past year as judged by the Investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Ain Témouchent
ZIP/Postal Code
46000
Country
Algeria
Facility Name
Novo Nordisk Investigational Site
City
Alger
ZIP/Postal Code
16000
Country
Algeria
Facility Name
Novo Nordisk Investigational Site
City
Algiers
ZIP/Postal Code
16000
Country
Algeria
Facility Name
Novo Nordisk Investigational Site
City
Constantine
ZIP/Postal Code
25000
Country
Algeria
Facility Name
Novo Nordisk Investigational Site
City
Oran
ZIP/Postal Code
31000
Country
Algeria
Facility Name
Novo Nordisk Investigational Site
City
Setif
ZIP/Postal Code
19000
Country
Algeria
Facility Name
Novo Nordisk Investigational Site
City
Sidi Bel Abbes
ZIP/Postal Code
22000
Country
Algeria
Facility Name
Novo Nordisk Investigational Site
City
Alexandria
ZIP/Postal Code
21131
Country
Egypt
Facility Name
Novo Nordisk Investigational Site
City
Casablanca
ZIP/Postal Code
20000
Country
Morocco
Facility Name
Novo Nordisk Investigational Site
City
Port Elizabeth
State/Province
Eastern Cape
ZIP/Postal Code
6014
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1812
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0002
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0083
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Vaderbijlpark
State/Province
Gauteng
ZIP/Postal Code
1900
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Durban
State/Province
KwaZulu-Natal
ZIP/Postal Code
4170
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Durban
State/Province
KwaZulu-Natal
ZIP/Postal Code
4450
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Kimberly
State/Province
Northern Cape
ZIP/Postal Code
8301
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7945
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Sandton
ZIP/Postal Code
2146
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Tunisia
ZIP/Postal Code
1053
Country
Tunisia

12. IPD Sharing Statement

Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk

Learn more about this trial

Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs

We'll reach out to this number within 24 hrs